retatrutide

News

Man looking through red lenses of binoculars

11 high-impact drugs to look out for in 2026

Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.

News

Lilly's obesity triple pulls off 29% weight loss in trial

Eli Lilly has ramped up the competition in weight-loss therapies by reporting the first pivotal data with its triple therapy retatrutide.

News

Lilly ends ADA on a high as obesity triple data pops

The first reveal of clinical data with Eli Lilly’s injectable triple receptor agonist for obesity suggests that the company could have a big winner on its hands if the dru

11 high-impact drugs to look out for in 2026

Lilly's obesity triple pulls off 29% weight loss in trial

Lilly ends ADA on a high as obesity triple data pops

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks